PD 168368 |
| Katalog-Nr.GC44584 |
PD 168368 ist ein potenter, kompetitiver und selektiver Neuromedin-B-Rezeptor (NMB-R)-Antagonist mit einem Ki von 15-45 nM. PD 168368 ist ein Antagonist des Neuromedin-B-Rezeptors (NMBR; IC50=96 nM)/Gastrin-Releasing-Peptid-Rezeptors (GRPR IC50=3500 nM). PD 168368 ist auch ein gemischter FPR1/FPR2/FPR3-Agonist mit EC50-Werten von 0,57, 0,24 bzw. 2,7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 204066-82-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PD 168368 is a competitive antagonist of neuromedin B (NMB) receptors (Kis = 15-45 nM for rat and human receptors expressed in various cell lines). It blocks the elevation of intracellular calcium and release of inositol phosphate induced by NMB in cells expressing NMB receptors. PD 168368 is selective for NMB receptors over those for related peptide agonists, including bombesin and gastrin-releasing peptide. It is also an agonist of formyl-peptide receptors (FPRs) at higher concentrations (EC50s = 0.57 and 0.24 µM for FPR1 and FPR2, respectively). PD 168368 induces cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells and blocks neovascularization and cancer cell growth in breast cancer xenograft tumors in mice.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *